Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EBITDA (2016 - 2025)

Iradimed (IRMD) has disclosed EBITDA for 13 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 18.04% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.9 million, a 16.55% increase, with the full-year FY2024 number at $22.0 million, up 9.63% from a year prior.
  • EBITDA was $6.8 million for Q3 2025 at Iradimed, up from $6.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $6.8 million in Q3 2025 to a low of $1.8 million in Q1 2021.
  • A 5-year average of $4.6 million and a median of $4.7 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 377.64% in 2021, then decreased 1.97% in 2024.
  • Iradimed's EBITDA stood at $3.1 million in 2021, then soared by 36.8% to $4.3 million in 2022, then increased by 21.3% to $5.2 million in 2023, then rose by 12.41% to $5.8 million in 2024, then rose by 17.82% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EBITDA are $6.8 million (Q3 2025), $6.8 million (Q2 2025), and $5.4 million (Q1 2025).